Feb 27, 2018   SOURCE: PR NewsWire

PharmaBoardroom Releases 'Healthcare and Life Sciences Review Serbia 2018'

LONDON, February 27, 2018 /PRNewswire/ --

PharmaBoardroom today releases its new 42-page Healthcare & Life Sciences Review Serbia 2018. [https://pharmaboardroom.com/pharma_report/serbia-pharma-report-2018 ]

Situated on the edge of Europe and with a reputation scarred by the conflicts of the 1990s, Serbia is not often considered a promising investment destination within Europe, far less for its healthcare and life science industries. Sluggish economic growth and a regulatory system unconducive to the introduction of innovative pharmaceutical products has meant that the country has been out of the international limelight for a number of years.

However, change is in the air and new perspectives are developing both of and for Serbia and its people. Economic and political stability; the gradual alignment of procedures and standards as Serbia continues its path towards EU membership; a talented and well-educated human resource base; changing attitudes at government level towards healthcare; and the realization that Serbia can act as a well-connected hub to serve over 20 million people across the Balkans are all contributing to a new and more positive image of the country.

This report [https://pharmaboardroom.com/pharma_report/serbia-pharma-report-2018 ] features the insights of international innovators who have navigated their way through difficult times and are now seeing the green shoots of optimism; the major learnings from domestic companies that have looked beyond Serbia's borders to find funding, best practices and export opportunities from abroad; as well as the advice of the local 'fixers' and service providers without whom the Serbian market could not operate.

Through the comments of these key personalities, a picture emerges of a nation not without its issues but with a potentially bright future and a pharmaceutical industry that holds numerous opportunities for bold international investors.

Interviews 

The report features in-depth interviews with: 

        
        - Bojan Trkulja, INOVIA
        - Predrag Bogavac, Novartis
        - Ronald Seeliger, Hemofarm
        - Goram M. Orlic, INNventa
        - Predrag Lukic, Amicus
        - Nebojsa Skuljec, MSD
        - Yan Mikhailova, Nestle

Quotes 

"It is the time for the government to realize the crucial need for innovation, especially in our industry" -Bojan Trkulja, INOVIA

"It is the process of joining the European Union that counts and not so much the date that Serbia joins" - Sanja Ivanic, CCFS

"The Serbian government took a very important step last year when they unblocked reimbursement for oncology products as one of the four priority therapeutic areas" - Predrag Bogavac, Novartis

"Serbia is an excellent investment destination with a very highly skilled and well-educated workforce, a competitive tax burden, a relatively stable macroeconomic outlook and we are in the process of entering the EU, which brings general predictability as to how our policies will develop." - Vera Nikolic, AmCham

Click here [https://pharmaboardroom.com/pharma_report/serbia-pharma-report-2018 ] to register and download the report.

SOURCE PharmaBoardroom